Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
-
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
-
Immuneering to Present at the Jefferies Global Healthcare Conference
-
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
-
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
-
Immuneering Corporation Announces Grant of Inducement Award
-
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
-
IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
-
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
-
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference